Published on 12 May 2022 on Zacks via Yahoo Finance
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
Catalyst Pharmaceuticals, Inc. CPRX reported earnings of 12 cents per share in the first quarter of 2022, which miss the Zacks Consensus Estimate of 14 cents. The company had reported earnings of 7 cents in the year-ago quarter.
Adjusted earnings (adjusted for stock-based compensation, depreciation and tax provision) came in at 18 cents per share in the reported quarter compared with 11 cents a year ago.
Total revenues of $43.1 million were in line with the Zacks Consensus Estimate. Sales rose 42.7% from the year-ago quarter’s $30.2 million. The top line primarily comprised sales of Firdapse (amifampridine), the company’s first approved drug for the treatment of Lambert-Eaton myasthenic syndrome (“LEMS”), and nominal license and other revenues.